Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device

The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.

Inclusion Criteria:

• Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks
• Subjects who meets the indication of EutropinPen inj.

Exclusion Criteria:

• Subjects who has diseases below on screening visit

  • Diabetes
  • Malignant tumor
  • Epiphyseal closure
  • Chronic kidney disease (recieved kidney transplantation)
  • Acute respitory failure